Table 2

Association of the DRB1*16:02-DQA1*01:02-DQB1*05:02 haplotype with GD with or without clinical eye disease

DRB1*16:02DQA1*01:02DQB1*05:02ControlsGD without clinical eye phenotype groupProptosis GroupMyogenic group
(2 n=822, %)(2 n=148, %)Pc*OR(2 n=164, %)Pc†OR(2 n=232, %)Pc‡OR
+++39 (4.7)17 (11.5)NS27 (16.5)3.9×10−6 4.045 (19.0)3.2×10−11 4.8
627 (76.3)104 (70.3)NS119 (72.6)NS146 (63.0)4.6×10−3 0.5
+105 (12.8)15 (10.1)NS9 (5.5)NS22 (9.0)NS
+32 (3.9)6 (4.1)NS3 (1.8)NS10 (4.0)NS
++19 (2.3)6 (4.1)NS6 (3.7)NS9 (4.0)NS
+0 (0)0 (0)NS0 (0)NS0 (0.0)NS
++0 (0)0 (0)NS0 (0)NS0 (0.0)NS
++0 (0)0 (0)NS0 (0)NS0 (0.0)NS
  • *Pc: GD without clinical eye phenotype group vs controls.

  • †Pc: proptosis group vs controls.

  • ‡Pc: myogenic group vs controls.

  • The p value was calculated using χ2 test or Fisher’s exact test and corrected for 93 tests performed.

  • HLA, human leucocyte antigen; NS, not significant; OR, odds ratio; Pc, corrected p value.